Q2 2021 EPS Estimates for Genmab A/S (NASDAQ:GMAB) Decreased by Truist Securiti
Genmab A/S (NASDAQ:GMAB) – Stock analysts at Truist Securiti dropped their Q2 2021 earnings per share (EPS) estimates for Genmab A/S in a note issued to investors on Thursday, February 25th. Truist Securiti analyst A. Goonewardene now forecasts that the company will post earnings of $0.06 per share for the quarter, down from their prior forecast of $0.11. Truist Securiti also issued estimates for Genmab A/S’s Q3 2021 earnings at $0.10 EPS and FY2024 earnings at $1.38 EPS. Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Monday, February 22nd. The company reported $0.14 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.12 by $0.02. Genmab A/S had a net margin of 50.99% and a return on equity of 34.40%.
Several other research firms have also recently weighed in on GMAB. Zacks Investment Research cut shares of Genmab A/S from a “hold” rating to a “sell” rating in a research report on Friday. DNB Markets cut shares of Genmab A/S from a “hold” rating to a “sell” rating in a research report on Monday, January 25th. Morgan Stanley cut shares of Genmab A/S from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 19th. Danske upgraded shares of Genmab A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, February 24th. Finally, TheStreet lowered shares of Genmab A/S from a “b” rating to a “c+” rating in a research note on Tuesday, December 1st. Four investment analysts have rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company’s stock. Genmab A/S presently has a consensus rating of “Hold” and an average target price of $42.63.
GMAB opened at $33.87 on Monday. Genmab A/S has a twelve month low of $16.24 and a twelve month high of $44.83. The company has a fifty day moving average of $41.04 and a 200-day moving average of $38.27. The stock has a market cap of $22.20 billion, a PE ratio of 26.26, a price-to-earnings-growth ratio of 2.91 and a beta of 0.93.
Several institutional investors have recently added to or reduced their stakes in GMAB. Private Advisor Group LLC lifted its stake in shares of Genmab A/S by 5.0% in the third quarter. Private Advisor Group LLC now owns 11,369 shares of the company’s stock valued at $399,000 after buying an additional 546 shares in the last quarter. Signaturefd LLC lifted its stake in shares of Genmab A/S by 100.1% in the third quarter. Signaturefd LLC now owns 7,270 shares of the company’s stock valued at $266,000 after buying an additional 3,636 shares in the last quarter. Raymond James & Associates lifted its position in shares of Genmab A/S by 4.1% during the third quarter. Raymond James & Associates now owns 78,531 shares of the company’s stock valued at $2,875,000 after purchasing an additional 3,081 shares in the last quarter. Raymond James Financial Services Advisors Inc. bought a new position in shares of Genmab A/S during the third quarter valued at about $231,000. Finally, Avalon Investment & Advisory bought a new position in shares of Genmab A/S during the third quarter valued at about $836,000. 6.24% of the stock is currently owned by hedge funds and other institutional investors.
Genmab A/S Company Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Featured Story: Straddles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Portfolio
Almost everyone loves a company that pays strong dividends. Who doesn’t like receiving a check every quarter for simply owning a stock–especially if that stock is paying you back 4%, 5% or even 10% of its share price in annual income each year?. In a world where 10-year treasuries are yielding just above 2%, it seems hard to go wrong when buying a stock that’s yielding significantly above the going rates on fixed-income assets. Unfortunately, the market rarely offers a free lunch.
While high-yield stocks may have a lot of near-term attractiveness, those same high-yields can often signal significant danger ahead. In some cases, it might mean that the company’s dividend will stop growing or won’t grow as fast as it used to. Worse yet, the company could cut its dividend, reduce the income you receive from owning the stock and drive down the value of the shares that you own.
4%-plus yields might seem like an easy opportunity to boost the investment income you receive, but high-yield stocks can just as often be a track reading to snare unsuspecting investors. It’s not always easy to tell the difference though.
This slideshow highlights 10 high-yield dividend stocks that are paying an unsustainably large percentage of their earnings in the form of a dividend. These companies are all paying out more than 100% of their earnings per share in the form of a dividend, a sign that the advertised high-yield probably won’t last.
View the “20 High-Yield Dividend Stocks that Could Ruin Your Retirement Portfolio”.
Published at Mon, 01 Mar 2021 07:41:15 +0000